(Total Views: 241)
Posted On: 06/29/2017 2:17:21 PM
Post# of 72446
Re: starboardtack #35377
False. If two Phase 3 ABSSSI trials cost $30M, why would a single Phase 3 Prurisol trial with fewer patients (see 505(b)(2) pathway) cost $30M?
Let's say P matches Otezla and for some crazy reasons no BP is interested so Leo is forced to advance it alone. I'll also assume one Phase 3 cost $15M (maximum) and the SP is $2 (minimum) after positive result is announced. So it'll take 7.5M shares (5.7% dilution) from the $42.8M shelf registration. Problems?
Dilutions are part of the game and it takes money to make money. So what was your concern again?
Let's say P matches Otezla and for some crazy reasons no BP is interested so Leo is forced to advance it alone. I'll also assume one Phase 3 cost $15M (maximum) and the SP is $2 (minimum) after positive result is announced. So it'll take 7.5M shares (5.7% dilution) from the $42.8M shelf registration. Problems?
Dilutions are part of the game and it takes money to make money. So what was your concern again?
Quote:
Either of these would be north of $30M IMO.
(6)
(0)
